Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis

Completed · Not applicable

Conditions studied: Sarcoidosis

In brief

The purpose of this research study to find out if a drug called OctreoScan or DOTATATE can help doctors diagnose people with cardiac sarcoidosis better. OctreoScan and DOTATATE are both approved by the U.S. Food and Drug Administration (FDA) to diagnose certain tumors.

Key facts

Study ID

NCT02546388

Run by

Marcelo F. Di Carli, MD, FACC

People needed

17

Starts

2015-10-01

Expected to finish

2018-08-01

Last updated by the study team

2020-04-09

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Individuals aged 18 or older
• Documentation of biopsy-proven sarcoidosis OR patients with typical findings on FDG PET and MRI without previous biopsy
• Clinical suspicion of cardiac involvement defined as the presence of any of the following: high-degree A-V nodal block, complete bundle branch block, reduced left or right ventricular systolic function, any cardiac arrhythmia, and/or unexplained chest pain, dyspnea or syncope
• PET/CT imaging demonstrating abnormal myocardial FDG uptake consistent with active inflammatory myocardium.

You may not qualify if…

• Initiation of steroids or any other immunosuppressive medication(s) following the completion of FDG-PET, as these medications, in theory, may subsequently suppress OctreoScan or DOTATATE uptake in the heart.
• Patients with history of neuroendocrine tumors (specially insulinomas)
• Patients taking the medication Octreotide
• Patients on total parenteral nutrition (TPN)
• Women who are pregnant or breastfeeding

Where it is running

• Brigham and Women's Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.